Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: a potential role in preservation of beta-cell mass

Eur Rev Med Pharmacol Sci. 2016 Jul;20(15):3313-8.


Several studies have evaluated the role of inflammation in type 1 diabetes (T1D). The safety profile and anti-inflammatory properties of high dose omega-3 fatty acids combined with Vitamin D supplementation make this therapy a possible candidate for T1D intervention trials. Herein, we describe the case of a 14-year-old boy with new onset T1D treated with high dose Omega-3 and vitamin D3. By 12 months, peak C-peptide increased to 0.55 nmol/L (1.66 ng/mL) corresponding to a 20% increment from baseline and AUC C-peptide was slightly higher compared to 9 months (0.33 vs. 0.30 nmol/L/min) although remaining slightly lower than baseline. Combination high-dose Omega-3 fatty acids and high-dose vitamin D3 therapy was well tolerated and may have beneficial effects on beta-cell function. Randomized controlled trials could be of assistance to determine whether this therapy may result in the preservation of beta-cell function in patients with new onset T1D.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / physiology
  • C-Peptide / metabolism*
  • Cholecalciferol / therapeutic use*
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Dietary Supplements
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Fatty Acids, Omega-3 / therapeutic use*
  • Humans
  • Hypoglycemic Agents
  • Immunity, Cellular / drug effects
  • Immunity, Cellular / immunology
  • Male
  • Treatment Outcome


  • C-Peptide
  • Fatty Acids, Omega-3
  • Hypoglycemic Agents
  • Cholecalciferol